Enovis Corporation (NYSE:ENOV – Get Free Report) traded down 4.2% on Thursday . The stock traded as low as $21.17 and last traded at $21.0550. 73,497 shares were traded during trading, a decline of 93% from the average session volume of 1,042,203 shares. The stock had previously closed at $21.97.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on the company. Zacks Research lowered Enovis from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 1st. Evercore reissued an “outperform” rating and issued a $36.00 target price on shares of Enovis in a report on Friday, May 8th. Needham & Company LLC boosted their target price on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. William Blair assumed coverage on Enovis in a report on Friday, April 17th. They issued an “outperform” rating on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and a consensus target price of $44.50.
Get Our Latest Research Report on ENOV
Enovis Stock Performance
Enovis (NYSE:ENOV – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The firm had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, sell-side analysts expect that Enovis Corporation will post 3.65 EPS for the current year.
Institutional Trading of Enovis
A number of hedge funds have recently bought and sold shares of ENOV. AQR Capital Management LLC increased its position in Enovis by 12.5% during the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after acquiring an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Enovis by 37.6% during the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock valued at $10,226,000 after acquiring an additional 73,116 shares during the last quarter. Empowered Funds LLC increased its position in Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after acquiring an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the last quarter. Finally, Amundi increased its position in Enovis by 24,405.0% during the second quarter. Amundi now owns 9,802 shares of the company’s stock valued at $328,000 after acquiring an additional 9,762 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.
Enovis Company Profile
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
Featured Articles
- Five stocks we like better than Enovis
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
